Get to know our clinical trials
Clinical trial of RVU120 in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia, relapsed or refractory, with or without NPM1 mutation.
THE PURPOSE OF THE STUDY IS TO INVESTIGATE RVU120 FOR THE TREATMENT OF RELAPSED (THAT HAVE RECURRED) OR REFRACTORY (THAT DO NOT RESPOND TO TREATMENT OR HAVE STOPPED RESPONDING TO TREATMENT) HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS-AR) AND ACUTE MYELOID LEUKEMIA (AML) AND YOU HAVE NOT RESPONDED TO PREVIOUS TREATMENT AND CANNOT GET BENEFIT FROM APPROVED TREATMENTS.
Technical Summary
- OPEN-LABEL, MULTICENTER CLINICAL TRIAL OF RVU120 IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA, RELAPSED OR REFRACTORY, WITH OR WITHOUT NPM1 MUTATION.
- Code EudraCT: 2023-505910-10-00
- Protocol number: RIVER-52
- Promoter: Ryvu Therapeutics S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.